Joan Carles

Has grant

ASSOCIATED PROFESSOR

University of Barcelona

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Study on differences in gene expression between clinically significant prostate cancer and latent and incidental varieties

Open Date: 2007-01-01

Close Date: 2009-12-01

Grant: Close

Role of MKP1 and NK-KB in reversing chemo resistance: analysis in vitro, ex vivo and of expression in human tumors

Open Date: 2006-01-01

Close Date: 2008-08-01

Grant: Close

Pharmacogenomic study of the polymorphisms in DNA repair genes in patients with head and neckcancer

Open Date: 2003-12-01

Close Date: 2006-11-01

Grant: Close

Spanish multicenter studyofgenetic and clinicalfactorsassociated withbladdercancer prognosis

Open Date: 2000-03-01

Close Date: 2003-03-01

Grant: Close

Structural alterations of mucoproteins in neoplastic cells: molecular basisand application

Open Date: 1997-03-01

Close Date: 2000-03-01

Articles (10)

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Howard Gurney

Macquarie University

AUSTRALIA

View details

Kim Chi

Chief Medical Officer

BC Cancer

CANADA

View details

Giorgio V Scagliotti

University of Turin

ITALY

View details

Stéphane Oudard

Université Paris-Saclay

FRANCE

View details

Yousef Zakharia

The University of Iowa

UNITED STATES

View details

Brooke Wilson

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Joan Carles

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer

Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]

A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma

A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

Collaborators (6)

Howard Gurney

Kim Chi

Giorgio V Scagliotti

Stéphane Oudard

Yousef Zakharia

Brooke Wilson

Make your next move.